The estimated Net Worth of Nadav Kidron is at least $6.28 Milion dollars as of 16 March 2023. Mr. Kidron owns over 26,000 units of Oramed Pharmaceuticals, Inc stock worth over $299,880 and over the last 17 years he sold ORMP stock worth over $4,424,200. In addition, he makes $1,551,100 as President, Chief Executive Officer oraz Director at Oramed Pharmaceuticals, Inc.
Nadav has made over 9 trades of the Oramed Pharmaceuticals, Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 26,000 units of ORMP stock worth $53,040 on 16 March 2023.
The largest trade he's ever made was selling 220,000 units of Oramed Pharmaceuticals, Inc stock on 9 August 2021 worth over $4,424,200. On average, Nadav trades about 11,404 units every 94 days since 2007. As of 16 March 2023 he still owns at least 126,000 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Mr. Kidron stock trades at the bottom of the page.
Nadav Kidron serves as President, Chief Executive Officer, Director of the Company. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel, and is a member of the Israel Bar Association.
As the President, Chief Executive Officer oraz Director of Oramed Pharmaceuticals, Inc, the total compensation of Nadav Kidron at Oramed Pharmaceuticals, Inc is $1,551,100. There are no executives at Oramed Pharmaceuticals, Inc getting paid more.
Nadav Kidron is 46, he's been the President, Chief Executive Officer oraz Director of Oramed Pharmaceuticals, Inc since 2006. There are 12 older and 2 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank oraz Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: